---
title: upfront treatment of acute myelogenous leukemia (AML)
date: "2023-01-22"
enableToc: false
---

> [!info]
>
> 🌱 來自: [[acute myelogenous leukemia (AML)]]

# upfront treatment of acute myelogenous leukemia (AML)

## [[Induction 7+3|什麼是七加三?]]

## FLT3-ITD/TKD mutation

- 7+3+ [[midostaurin]] 👉 ❌ FLT3
- [[flt3.md|FLT3]]

## Core-binding factor

t(8;21) or inv(16): 7+3 ± [[gemtuzumab ozogamicin|GO是CD多少的inhitbitor?]] (CD33)

## 2° AML or w/ MDS-related changes

- CPX-351 (liposomal Ara-C & daunorubicin)

---

- <60 y: 7+3 (high-dose daunorubicin 90 mg/m2);
- > 60 y: dauno 60 mg/m2

---

## Regimens for **unfit**

(may include age ≥75 y or < 75y w/ ECOG ≥3 or severe cardiac or pulmonary comorbidity; Leukemia 2013;27:997)

- Azacitadine + venetoclax (Bcl2 inhibitor) (NEJM 2020;383:617)

[[IDH1_IDH2 mutation]]: ivosidenib or enasedinib
